ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $10,650,885 | -6.1% | 263,375 | +8.1% | 0.04% | -2.4% |
| Q4 2022 | $11,337,761 | -10.3% | 243,718 | 0.0% | 0.04% | -22.2% |
| Q3 2022 | $12,641,000 | +17.4% | 243,718 | +7.0% | 0.05% | +25.6% |
| Q2 2022 | $10,768,000 | -80.8% | 227,807 | -71.1% | 0.04% | -76.6% |
| Q1 2022 | $56,183,000 | -22.5% | 789,311 | -18.6% | 0.18% | -23.0% |
| Q4 2021 | $72,516,000 | +31.6% | 969,736 | 0.0% | 0.24% | +17.7% |
| Q3 2021 | $55,090,000 | +3670.7% | 969,736 | +2820.9% | 0.20% | +3960.0% |
| Q2 2021 | $1,461,000 | -85.4% | 33,200 | -86.0% | 0.01% | -89.6% |
| Q4 2020 | $10,006,000 | -41.7% | 237,679 | -36.6% | 0.05% | -45.5% |
| Q3 2020 | $17,162,000 | -13.3% | 374,885 | -4.9% | 0.09% | -22.8% |
| Q2 2020 | $19,792,000 | -6.6% | 394,197 | -4.4% | 0.11% | -16.8% |
| Q1 2020 | $21,199,000 | -37.2% | 412,197 | -24.6% | 0.14% | -18.9% |
| Q4 2019 | $33,752,000 | +10.5% | 546,331 | +7.4% | 0.17% | +0.6% |
| Q3 2019 | $30,558,000 | -41.4% | 508,630 | -17.7% | 0.17% | -41.9% |
| Q2 2019 | $52,127,000 | -17.9% | 617,771 | -7.1% | 0.29% | -21.3% |
| Q1 2019 | $63,514,000 | +31.9% | 664,934 | -2.2% | 0.37% | +22.3% |
| Q4 2018 | $48,145,000 | -19.3% | 679,734 | -2.7% | 0.30% | -5.7% |
| Q3 2018 | $59,688,000 | -9.6% | 698,434 | +22.7% | 0.32% | -16.3% |
| Q2 2018 | $65,994,000 | -6.4% | 569,408 | -34.7% | 0.38% | -5.2% |
| Q1 2018 | $70,535,000 | +10.9% | 871,775 | -19.6% | 0.40% | +14.9% |
| Q4 2017 | $63,620,000 | +43.5% | 1,084,200 | +14.5% | 0.35% | +37.4% |
| Q3 2017 | $44,324,000 | +31.8% | 947,100 | +1.3% | 0.25% | +29.6% |
| Q2 2017 | $33,630,000 | +24.3% | 934,700 | +6.4% | 0.20% | +21.7% |
| Q1 2017 | $27,057,000 | +66.7% | 878,500 | +81.3% | 0.16% | +62.6% |
| Q4 2016 | $16,230,000 | +252.0% | 484,500 | +179.6% | 0.10% | +253.6% |
| Q3 2016 | $4,611,000 | – | 173,300 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |